Handelsavisen
prelaunch
Companies Healthcare 084650.KQ
08
084650.KQ KOSDAQ Healthcare Facilities & Services

084650.Kq

$1 086,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
80,6B KRW
P/E
EV / Rev
Div yield
0,00 %
Op margin
-67,9 %
ROE
-43,0 %
Net margin
-73,0 %
Debt / equity
0,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.

Business. The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-43,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 084650.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 084650.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidity is assessed as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The price-to-book ratio of 0.65 and the price-to-tangible-book ratio of 0.65 indicate that the company's market value is trading at a discount to its book value, which may reflect market concerns about its financial health or future earnings potential.

    Profitability metrics show a return on equity of -0.4302 and a return on assets of -0.2797, both of which are significantly below the industry median and indicate a loss-making position. The company's operating income and net income are negative, at -59.89 billion KRW and -64.37 billion KRW, respectively, which further underscores the poor financial performance. These figures suggest that the company is not generating sufficient revenue to cover its operating costs and is experiencing a decline in profitability.

    The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification may expose the company to higher risks if market conditions in its primary segment or region deteriorate. The absence of detailed segment and geographic data limits the ability to assess the company's exposure to different markets and potential for growth.

    The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year indicates a continuation of this trend, with no positive revenue growth expected. The company's operating cash flow is negative at -30.54 billion KRW, and its free cash flow is also negative at -55.73 billion KRW, which suggests that the company is not generating enough cash to sustain operations or fund growth initiatives. The capital expenditure of -1.66 billion KRW indicates a reduction in investment in long-term assets, which may affect future growth potential.

    The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's negative operating and net income, along with its negative cash flows, may necessitate future financing activities that could lead to dilution. The company's financial performance and liquidity position suggest that it may need to seek additional capital, which could involve issuing new shares or taking on more debt.

    Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The financial snapshot indicates a challenging operating environment, with the company reporting significant losses and negative cash flows. The absence of recent events or transcripts limits the ability to assess the company's response to these challenges or its plans for improvement.

    Key takeaways
    • The company is currently experiencing significant financial losses, with negative operating and net income.
    • The company's liquidity position is medium, with negative net cash after subtracting total debt.
    • The company's profitability metrics are well below the industry median, indicating poor financial performance.
    • The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.37.
    • The company's growth trajectory is negative, with no positive revenue growth expected in the current fiscal year.
    • The company's market value is trading at a discount to its book value, which may reflect market concerns about its financial health.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 086,00
    Market cap
    $96.66B
    Enterprise value
    $152.16B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.7x
    P / Tangible book
    0.7x
    Tangible book
    $149.62B
    Net cash
    -$55.50B
    Current ratio
    1.2
    Debt / equity
    0.4
    ROA
    -28.0%
    ROE
    -43.0%
    Cash conversion
    47.0%
    CapEx / revenue
    -1.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-67,9 %Bottom quartile
    Net Margin-73,0 %Bottom quartile
    ROE-43,0 %Bottom quartile
    Capex / Rev-1,9 %Above P75
    D/E0,37Above median
    Cash Conv0,47Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 084650.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    084650.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage